Drug Profile
Research programme: GPCR targeting antibodies - MorphoSys
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator MorphoSys
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Undefined in Germany (Parenteral)
- 15 Sep 2014 Early research in Undefined indication in Germany (Parenteral)